Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARCUS CORPMCS · Entity 5078 | Director | May 21, 2026 | May 27, 2026 |
| SteadyMed Ltd.STDY · Entity 163743 | Director · 10% owner | August 30, 2018 | September 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARCUS CORP
Report date May 21, 2026 · Filed May 27, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,206 |
Reported balance
After 2026-05-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,391 · Balance 48,206 F1: Granted by Issuer in consideration of service as a director. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.55 · Expires 2026-12-29 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.20 · Expires 2027-12-28 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2027-12-27 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.60 · Expires 2029-12-26 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.95 · Expires 2031-12-30 | Direct | 750 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance 750 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.25 · Expires 2032-12-29 | Direct | 1,438 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance 1,438 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. F3: Amending solely to correct previously reported Underlying Securities reported in dollars to be reported in shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.69 · Expires 2033-12-28 | Direct | 1,455 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · Balance 1,455 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted by Issuer in consideration of service as a director.
F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan.
F3: Amending solely to correct previously reported Underlying Securities reported in dollars to be reported in shares.
SteadyMed Ltd.
Report date August 30, 2018 · Filed September 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-30 · Sale · Disposed 2,937,938 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-08-30 · Sale · Disposed 1,166,428 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-08-30 · Sale · Disposed 15,780 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F3: By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-08-30 · Sale · Disposed 253,309 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F4: By Brian Stark and Debra Altshul Stark. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Debra Altshul Stark | 0 |
Reported balance
After 2018-08-30 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-08-30 · Sale · Disposed 323,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2025-08-06 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-08-30 · Other · Disposed 33,350 · Balance 0 F5: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2026-10-05 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-08-30 · Other · Disposed 3,875 · Balance 0 F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2027-12-28 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-08-30 · Other · Disposed 21,029 · Balance 0 F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2021-08-03 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-08-30 · Other · Disposed 939,428 · Balance 0 F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2022-04-24 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-08-30 · Other · Disposed 209,650 · Balance 0 F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2021-08-03 | IndirectSee Footnote. | 0 |
Reported balance
After 2018-08-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-08-30 · Other · Disposed 371,375 · Balance 0 F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2022-04-24 | IndirectSee Footnote. | 0 |
Reported balance
After 2018-08-30 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-08-30 · Other · Disposed 41,875 · Balance 0 F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone").
F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP.
F3: By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust.
F4: By Brian Stark and Debra Altshul Stark.
F5: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.
F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71.
F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 27, 2026 01:33 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,391 | $17.97 | $24,996.27 |
DisclosureSEC source: 0000897069-26-001257 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,206 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| May 21, 2026 Filed May 27, 2026 21:07 UTC Amendment | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,391 | $17.97 | $24,996.27 |
DisclosureSEC source: 0000897069-26-001273 · form4a.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,206 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 00:12 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 4,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000052 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,815 F1 · kind: Restricted stock granted December 31, 2025 vests and becomes exercisable as follows: 50% after 2nd anniversary of date of grant and 100% after 4th anniversary of date of grant. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:16 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,538 | $16.25 | $24,992.50 |
DisclosureSEC source: 0000897069-25-000957 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,641 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 23:44 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 2,956 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-002341 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,103 F1 · kind: Restricted stock granted December 26, 2024 vests and becomes exercisable as follows: 50% after 2nd anniversary of date of grant and 100% after 4th anniversary of date of grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:16 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 2,154 | $11.60 | $24,986.40 |
DisclosureSEC source: 0000897069-24-001219 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,147 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 23:46 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,455 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000897069-24-000034 · form4.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,455 Underlying: Common Stock · 1,455 shares Expires 2033-12-28 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 23:46 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 3,113 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000034 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,993 F1 · kind: Restricted stock granted December 28, 2023 vests and becomes exercisable as follows: 50% after 2nd anniversary of date of grant and 100% after 4th anniversary of date of grant. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:59 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0000897069-23-000600 · form4.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2023-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:59 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionCommon Stock | 1,000 | $13.45 | $13,450.00 |
DisclosureSEC source: 0000897069-23-000600 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2023 Filed May 26, 2023 00:28 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,510 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-000585 · form4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,880 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:54 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,438 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001567619-23-000063 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438 Underlying: Common Stock · 1,438 shares Expires 2032-12-29 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:54 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 2,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000063 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,370 F1 · kind: Restricted stock granted December 29, 2022 vests and becomes exercisable as follows: 50% after 2nd anniversary of date of grant and 100% after 4th anniversary of date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 12:56 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001567619-22-011158 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 18, 2022 12:56 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionCommon Stock | 500 | $13.33 | $6,665.00 |
DisclosureSEC source: 0001567619-22-011158 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2022 Filed May 11, 2022 20:35 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-010071 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,884 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 22:50 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001567619-22-000872 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2022-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 22:50 UTC | MARCUS CORP MCS · Entity 5078 | Exercise / conversionCommon Stock | 1,000 | $12.89 | $12,890.00 |
DisclosureSEC source: 0001567619-22-000872 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 23:55 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001567619-22-000083 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires 2031-12-30 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 23:55 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000083 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,326 F1 · kind: Restricted stock granted December 30, 2021 vests and becomes exercisable as follows: 50% after 2nd anniversary of date of grant and 100% after 4th anniversary of date of grant. Read SEC document |
| May 06, 2021 Filed May 10, 2021 13:15 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-009370 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,323 F1 · kind: Restricted stock granted May 6, 2021 vests and becomes exercisable as follows: 100% after the first anniversary of the date of grant. Read SEC document |
| May 06, 2021 Filed Jul 21, 2021 16:19 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013753 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,076 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| May 06, 2020 Filed May 8, 2020 17:11 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009291 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,823 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 22:28 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0001567619-19-023721 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2029-12-26 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 22:28 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-023721 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,070 F1 · kind: Restricted stock granted December 26, 2019 vests and becomes exercisable as follows: 50% after the 2nd anniversary of the date of grant and 100% after the 4th anniversary of the date of grant. Read SEC document |
| May 07, 2019 Filed May 9, 2019 17:27 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-010244 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,570 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 22:46 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $38.51 | $0.00 |
DisclosureSEC source: 0001567619-18-008808 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-12-27 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 22:46 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008808 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,817 F1 · kind: Restricted stock granted December 27, 2018 vests and becomes exercisable as follows: 50% after 2nd anniversary of the date of grant and 100% after 4th anniversary of the date of grant. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherWarrants to Purchase Ordinary Shares · Derivative | 41,875 | $0.13 Strike: $6.79 | $5,234.38 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 12 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote. Disclosed balance after: 0 Underlying: Ordinary Shares · 41,875 shares Expires 2022-04-24 F8 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. F8 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. F2 · ownership.nature: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherWarrants to Purchase Ordinary Shares · Derivative | 371,375 | $0.13 Strike: $3.60 | $46,421.88 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 11 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote. Disclosed balance after: 0 Underlying: Ordinary Shares · 371,375 shares Expires 2021-08-03 F7 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. F7 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. F2 · ownership.nature: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherWarrants to Purchase Ordinary Shares · Derivative | 209,650 | $0.13 Strike: $6.79 | $26,206.25 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 10 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 209,650 shares Expires 2022-04-24 F8 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. F8 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherWarrants to Purchase Ordinary Shares · Derivative | 939,428 | $0.13 Strike: $3.60 | $117,428.50 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 9 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 939,428 shares Expires 2021-08-03 F7 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. F7 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 21,029 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 8 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,029 shares Expires 2027-12-28 F6 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F6 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 3,875 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 7 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,875 shares Expires 2026-10-05 F6 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F6 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 33,350 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · derivative · entry 6 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,350 shares Expires 2025-08-06 F5 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time. F5 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 323,500 | $4.46 | $1,442,810.00 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · nonDerivative · entry 5 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Debra Altshul Stark Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 253,309 | $4.46 | $1,129,758.14 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · nonDerivative · entry 4 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F4 · ownership.nature: By Brian Stark and Debra Altshul Stark. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 15,780 | $4.46 | $70,378.80 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · nonDerivative · entry 3 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F3 · ownership.nature: By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 1,166,428 | $4.46 | $5,202,268.88 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · nonDerivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F2 · ownership.nature: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 23:44 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 2,937,938 | $4.46 | $13,103,203.48 |
DisclosureSEC source: 0001209191-18-049380 · doc4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). Read SEC document |
| May 08, 2018 Filed May 11, 2018 00:25 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022878 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,317 F1 · kind: Granted by Issuer in consideration of service as a director. Read SEC document |
| December 28, 2017 Filed Dec 28, 2017 19:36 UTC | SteadyMed Ltd. STDY · Entity 163743 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-17-067552 · doc4.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires 2027-12-28 F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested. Read SEC document |
| December 28, 2017 Filed Dec 28, 2017 19:36 UTC | SteadyMed Ltd. STDY · Entity 163743 | GrantStock Option (Right to Buy) · Derivative | 13,029 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-17-067552 · doc4.xml · derivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,029 Underlying: Ordinary Shares · 13,029 shares Expires 2027-12-28 F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 23:59 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $27.20 | $0.00 |
DisclosureSEC source: 0001140361-17-047854 · doc1.xml · derivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2027-12-28 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 23:59 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-047854 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,564 F1 · shares: Restricted stock granted December 28, 2017 vests and becomes exercisable as follows: 50% after 3rd anniversary of the date of the grant and 100% after 5th anniversary of the date of the grant or upon death, disability or retirement. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 21:06 UTC | SteadyMed Ltd. STDY · Entity 163743 | GiftOrdinary Shares | 15,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-050912 · doc4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Stark Family Trust Disclosed balance after: 0 F1 · kind: The reporting person is trustee of the Stark Family Trust. On August 22, 2017, August 23, 2017 and August 29, 2017, the reporting person caused the trust to distribute an aggregate of 15,780 shares of the Issuer's Ordinary Shares to beneficiaries of the trust. The reporting person disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:37 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-018870 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 F1 · price: Granted by Issuer in consideration of service as a director. Read SEC document |
| April 25, 2017 Filed Aug 22, 2017 20:17 UTC | SteadyMed Ltd. STDY · Entity 163743 | PurchaseWarrants to Purchase Ordinary Shares · Derivative | 41,875 | $0.13 Strike: $6.79 | $5,234.38 |
DisclosureSEC source: 0001209191-17-049817 · doc4.xml · derivative · entry 7 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 41,875 Underlying: Ordinary Shares · 41,875 shares Expires 2022-04-24 F4 · derivative.exercise_date: Warrants are fully vested and immediately exercisable. F2 · ownership.nature: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. Read SEC document |
| April 25, 2017 Filed Aug 22, 2017 20:17 UTC | SteadyMed Ltd. STDY · Entity 163743 | PurchaseWarrants to Purchase Ordinary Shares · Derivative | 209,650 | $0.13 Strike: $6.79 | $26,206.25 |
DisclosureSEC source: 0001209191-17-049817 · doc4.xml · derivative · entry 6 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,650 Underlying: Ordinary Shares · 209,650 shares Expires 2022-04-24 F4 · derivative.exercise_date: Warrants are fully vested and immediately exercisable. Read SEC document |
| April 25, 2017 Filed Aug 22, 2017 20:17 UTC | SteadyMed Ltd. STDY · Entity 163743 | PurchaseOrdinary Shares | 83,750 | $5.90 | $494,125.00 |
DisclosureSEC source: 0001209191-17-049817 · doc4.xml · nonDerivative · entry 2 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,166,428 F2 · ownership.nature: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.